Compare ARK Next Generation Internet ETF (ARKW) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Next Generation Internet ETF vs Crispr Therapeutics AG — how do they compare? ARK Next Generation Internet ETF trades at $150.74, while Crispr Therapeutics AG trades at $53.87 (market cap $5.23B). The key difference: ARK Next Generation Internet ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| ARKW | CRSP | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $182.20 | $76.78 |
52-Week Low | $114.45 | $44.34 |
Market Cap | — | $5.23B |
Enterprise Value | — | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $151.00, up 0.95% with bullish technical signals from moving averages. The ETF faces near-term headwinds from elevated AI infrastructure spending but maintains long-term growth potential through holdings like AMD and TSLA. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX indicates strong trend strength.
The ETF's outlook balances near-term capital expenditure pressures against long-term AI growth opportunities. Key risks include market skepticism toward tech valuations and sector volatility, while institutional interest in AI exposure provides support. Current positioning near resistance at $152 suggests potential for consolidation before next directional move.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Next Generation Internet ETF
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
